Kathleen Kelly, Crystal Stanley, Micaela Jones, Jeff Finlon, David Buesing, Maria Rahman, Michelle Poffel, Deanna Janosko, Susanne Marschner
{"title":"聚集在冷藏血小板单位有不同的表型,并通过输血前过滤器去除。","authors":"Kathleen Kelly, Crystal Stanley, Micaela Jones, Jeff Finlon, David Buesing, Maria Rahman, Michelle Poffel, Deanna Janosko, Susanne Marschner","doi":"10.1111/vox.70114","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>The US Food and Drug Administration guidance for cold-stored platelets (CSPs) permits storage of apheresis platelets at 1-6°C for ≤14 days. During a pilot programme, CSPs were evaluated in a large US blood centre over a 10-month period (September 2023 to July 2024) to better understand the formation of aggregates under routine use.</p><p><strong>Materials and methods: </strong>Platelets collected in 100% plasma were moved into cold storage within 4 h of collection and shipped to local hospitals. Hospitals returned any units with aggregates to the blood centre. Units were visually inspected and tested for platelet concentration, pH, metabolism and activation parameters. At expiration (Day 14), units were passed through a transfusion filter (170-260 μm) and assessed post-filtration and after 24 h.</p><p><strong>Results: </strong>Aggregation rates were high initially but decreased to 9% of released CSPs by study conclusion. Fifty-five aggregated units were returned. The majority of units (42%) had a small, flaky phenotype, which did not change over storage. Platelet counts significantly decreased with a 50% drop by expiry. Lactadherin and P-selectin increased, CD63 and CD41/61 complex decreased and there was slower metabolism. Filtration removed all aggregates, except for one unit with small aggregates being observed 24 h post-filtration. Platelet recovery after filtration was 94% ± 26%. Seven repeat donors donated 6 units with no aggregates and 17 units with aggregates, with variable aggregate phenotypes between donations.</p><p><strong>Conclusion: </strong>This study demonstrates that aggregate phenotypes in CSPs are highly variable and removed effectively by filtration; they appear to arise more from external handling conditions than from any intrinsic product property.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Aggregates in cold-stored platelet units have diverse phenotypes and are removed by pre-transfusion filters.\",\"authors\":\"Kathleen Kelly, Crystal Stanley, Micaela Jones, Jeff Finlon, David Buesing, Maria Rahman, Michelle Poffel, Deanna Janosko, Susanne Marschner\",\"doi\":\"10.1111/vox.70114\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objectives: </strong>The US Food and Drug Administration guidance for cold-stored platelets (CSPs) permits storage of apheresis platelets at 1-6°C for ≤14 days. During a pilot programme, CSPs were evaluated in a large US blood centre over a 10-month period (September 2023 to July 2024) to better understand the formation of aggregates under routine use.</p><p><strong>Materials and methods: </strong>Platelets collected in 100% plasma were moved into cold storage within 4 h of collection and shipped to local hospitals. Hospitals returned any units with aggregates to the blood centre. Units were visually inspected and tested for platelet concentration, pH, metabolism and activation parameters. At expiration (Day 14), units were passed through a transfusion filter (170-260 μm) and assessed post-filtration and after 24 h.</p><p><strong>Results: </strong>Aggregation rates were high initially but decreased to 9% of released CSPs by study conclusion. Fifty-five aggregated units were returned. The majority of units (42%) had a small, flaky phenotype, which did not change over storage. Platelet counts significantly decreased with a 50% drop by expiry. Lactadherin and P-selectin increased, CD63 and CD41/61 complex decreased and there was slower metabolism. Filtration removed all aggregates, except for one unit with small aggregates being observed 24 h post-filtration. Platelet recovery after filtration was 94% ± 26%. Seven repeat donors donated 6 units with no aggregates and 17 units with aggregates, with variable aggregate phenotypes between donations.</p><p><strong>Conclusion: </strong>This study demonstrates that aggregate phenotypes in CSPs are highly variable and removed effectively by filtration; they appear to arise more from external handling conditions than from any intrinsic product property.</p>\",\"PeriodicalId\":23631,\"journal\":{\"name\":\"Vox Sanguinis\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vox Sanguinis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/vox.70114\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vox Sanguinis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/vox.70114","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Aggregates in cold-stored platelet units have diverse phenotypes and are removed by pre-transfusion filters.
Background and objectives: The US Food and Drug Administration guidance for cold-stored platelets (CSPs) permits storage of apheresis platelets at 1-6°C for ≤14 days. During a pilot programme, CSPs were evaluated in a large US blood centre over a 10-month period (September 2023 to July 2024) to better understand the formation of aggregates under routine use.
Materials and methods: Platelets collected in 100% plasma were moved into cold storage within 4 h of collection and shipped to local hospitals. Hospitals returned any units with aggregates to the blood centre. Units were visually inspected and tested for platelet concentration, pH, metabolism and activation parameters. At expiration (Day 14), units were passed through a transfusion filter (170-260 μm) and assessed post-filtration and after 24 h.
Results: Aggregation rates were high initially but decreased to 9% of released CSPs by study conclusion. Fifty-five aggregated units were returned. The majority of units (42%) had a small, flaky phenotype, which did not change over storage. Platelet counts significantly decreased with a 50% drop by expiry. Lactadherin and P-selectin increased, CD63 and CD41/61 complex decreased and there was slower metabolism. Filtration removed all aggregates, except for one unit with small aggregates being observed 24 h post-filtration. Platelet recovery after filtration was 94% ± 26%. Seven repeat donors donated 6 units with no aggregates and 17 units with aggregates, with variable aggregate phenotypes between donations.
Conclusion: This study demonstrates that aggregate phenotypes in CSPs are highly variable and removed effectively by filtration; they appear to arise more from external handling conditions than from any intrinsic product property.
期刊介绍:
Vox Sanguinis reports on important, novel developments in transfusion medicine. Original papers, reviews and international fora are published on all aspects of blood transfusion and tissue transplantation, comprising five main sections:
1) Transfusion - Transmitted Disease and its Prevention:
Identification and epidemiology of infectious agents transmissible by blood;
Bacterial contamination of blood components;
Donor recruitment and selection methods;
Pathogen inactivation.
2) Blood Component Collection and Production:
Blood collection methods and devices (including apheresis);
Plasma fractionation techniques and plasma derivatives;
Preparation of labile blood components;
Inventory management;
Hematopoietic progenitor cell collection and storage;
Collection and storage of tissues;
Quality management and good manufacturing practice;
Automation and information technology.
3) Transfusion Medicine and New Therapies:
Transfusion thresholds and audits;
Haemovigilance;
Clinical trials regarding appropriate haemotherapy;
Non-infectious adverse affects of transfusion;
Therapeutic apheresis;
Support of transplant patients;
Gene therapy and immunotherapy.
4) Immunohaematology and Immunogenetics:
Autoimmunity in haematology;
Alloimmunity of blood;
Pre-transfusion testing;
Immunodiagnostics;
Immunobiology;
Complement in immunohaematology;
Blood typing reagents;
Genetic markers of blood cells and serum proteins: polymorphisms and function;
Genetic markers and disease;
Parentage testing and forensic immunohaematology.
5) Cellular Therapy:
Cell-based therapies;
Stem cell sources;
Stem cell processing and storage;
Stem cell products;
Stem cell plasticity;
Regenerative medicine with cells;
Cellular immunotherapy;
Molecular therapy;
Gene therapy.